This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

How Vifor used a decades-old health scare, skunks and academics to harm competition

By Nicholas Hirst ( January 3, 2025, 09:00 GMT | Comment) -- Pharma company CSL Vifor waged a multifaceted campaign to mislead doctors, pharmacists and others about the safety of a rival iron infusion, which is detailed in a newly published EU antitrust decision. That campaign sought to associate the rival treatment with deadly iron drugs from the 1950s. The decision warns dominant pharmaceutical companies not to use “real world evidence” collected outside controlled clinical trials to attack competitors.Employees of CSL Vifor, the manufacturer of a market-leading iron-deficiency treatment, at times recognized that they had no real scientific basis to claim their own product was safer than the closest rival. But they did it anyway.  ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections